Iluvien receives marketing authorization in Belgium

The Belgian Federal Agency for Medicines and Health Products has granted marketing approval for Iluvien to treat impaired vision associated with chronic diabetic macular edema, according to a press release from Alimera Sciences.With this approval, Iluvien (fluocinolone acetonide intravitreal implant) is now approved for marketing in 12 countries: Austria, Belgium, Denmark, France, Germany, Italy, Norway, Portugal, Spain, Sweden, the United Kingdom and the United States.